Analytical Data
-
Gene name
PON3
- Application
-
Alternative Names
PON3；Serum paraoxonase/lactonase 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15166
-
Expression Region
2-354aa
-
AA Sequence
GKLVALVLL GVGLSLVGEM FLAFRERVNA SREVEPVEPE NCHLIEELES GSEDIDILPS GLAFISSGLK YPGMPNFAPD EPGKIFLMDL NEQNPRAQAL EISGGFDKEL FNPHGISIFI DKDNTVYLYV VNHPHMKSTV EIFKFEEQQR SLVYLKTIKH ELLKSVNDIV VLGPEQFYAT RDHYFTNSLL SFFEMILDLR WTYVLFYSPR EVKVVAKGFC SANGITVSAD QKYVYVADVA AKNIHIMEKH DNWDLTQLKV IQLGTLVDNL TVDPATGDIL AGCHPNPMKL LNYNPEDPPG SEVLRIQNVL SEKPRVSTVY ANNGSVLQGT SVASVYHGKI LIGTVFHKTL YCEL
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PON3, or paraoxonase 3, is a member of the paraoxonase gene family, which plays a critical role in the metabolism of various lipid compounds and is associated with protective functions against oxidative stress and inflammation. Research into PON3 has gained momentum due to its emerging implications in cardiovascular diseases, metabolic disorders, and neurological conditions. Unlike its well-studied counterparts, PON1 and PON2, PON3 remains less understood, prompting investigations into its biochemical properties, substrate specificity, and functional roles in health and disease. Studies have suggested that PON3 may exhibit antioxidant capabilities and contribute to the detoxification of harmful lipids, making it a potential therapeutic target for conditions characterized by oxidative stress. Furthermore, understanding the mechanisms governing PON3's activity and regulation could provide insights into its involvement in lipid metabolism and its protective effects against atherosclerosis. Advances in recombinant protein technology have facilitated the production of PON3, enabling researchers to explore its structure-function relationships and develop potential clinical applications. As a result, PON3 is emerging as a molecule of interest in the fields of cardiovascular research, metabolic syndrome, and neuroprotection, highlighting the need for continued exploration of its therapeutic potential.
